{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T22:54:07Z","timestamp":1789858447094,"version":"4.0.1"},"reference-count":47,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"CVie Therapeutics Limited"},{"name":"Windtree Therapeutics"},{"name":"FAR2019 of the University of Milano-Bicocca"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,3,16]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Aims\u2003<\/jats:title>\n                  <jats:p>Diabetic cardiomyopathy is a multifactorial disease characterized by an early onset of diastolic dysfunction (DD) that precedes the development of systolic impairment. Mechanisms that can restore cardiac relaxation improving intracellular Ca2+ dynamics represent a promising therapeutic approach for cardiovascular diseases associated to DD. Istaroxime has the dual properties to accelerate Ca2+ uptake into sarcoplasmic reticulum (SR) through the SR Ca2+ pump (SERCA2a) stimulation and to inhibit Na+\/K+ ATPase (NKA). This project aims to characterize istaroxime effects at a concentration (100\u00a0nmol\/L) marginally affecting NKA, in order to highlight its effects dependent on the stimulation of SERCA2a in an animal model of mild diabetes.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods and results\u2003<\/jats:title>\n                  <jats:p>Streptozotocin (STZ) treated diabetic rats were studied at 9 \u2009weeks after STZ injection in comparison to controls (CTR). Istaroxime effects were evaluated in vivo and in left ventricular (LV) preparations. STZ animals showed (i) marked DD not associated to cardiac fibrosis, (ii) LV mass reduction associated to reduced LV cell dimension and T-tubules loss, (iii) reduced LV SERCA2 protein level and activity and (iv) slower SR Ca2+ uptake rate, (v) LV action potential (AP) prolongation and increased short-term variability (STV) of AP duration, (vi) increased diastolic Ca2+, and (vii) unaltered SR Ca2+ content and stability in intact cells. Acute istaroxime infusion (0.11\u00a0mg\/kg\/min for 15\u00a0min) reduced DD in STZ rats. Accordingly, in STZ myocytes istaroxime (100\u00a0nmol\/L) stimulated SERCA2a activity and blunted STZ-induced abnormalities in LV Ca2+ dynamics. In CTR myocytes, istaroxime increased diastolic Ca2+ level due to NKA blockade albeit minimal, while its effects on SERCA2a were almost absent.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions\u2003<\/jats:title>\n                  <jats:p>SERCA2a stimulation by istaroxime improved STZ-induced DD and intracellular Ca2+ handling anomalies. Thus, SERCA2a stimulation can be considered a promising therapeutic approach for DD treatment.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/cvr\/cvab123","type":"journal-article","created":{"date-parts":[[2021,3,31]],"date-time":"2021-03-31T11:34:52Z","timestamp":1617190492000},"page":"1020-1032","source":"Crossref","is-referenced-by-count":48,"title":["SERCA2a stimulation by istaroxime improves intracellular Ca2+ handling and diastolic dysfunction in a model of diabetic cardiomyopathy"],"prefix":"10.1093","volume":"118","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1822-8495","authenticated-orcid":false,"given":"Eleonora","family":"Torre","sequence":"first","affiliation":[{"name":"Department of Biotechnology and Biosciences, Universit\u00e0 degli Studi di Milano-Bicocca, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6509-4894","authenticated-orcid":false,"given":"Martina","family":"Arici","sequence":"additional","affiliation":[{"name":"Department of Biotechnology and Biosciences, Universit\u00e0 degli Studi di Milano-Bicocca, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1275-6329","authenticated-orcid":false,"given":"Alessandra Maria","family":"Lodrini","sequence":"additional","affiliation":[{"name":"Department of Biotechnology and Biosciences, Universit\u00e0 degli Studi di Milano-Bicocca, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2390-2851","authenticated-orcid":false,"given":"Mara","family":"Ferrandi","sequence":"additional","affiliation":[{"name":"Windtree Therapeutics Inc., Warrington, PA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Barassi","sequence":"additional","affiliation":[{"name":"Windtree Therapeutics Inc., Warrington, PA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shih-Che","family":"Hsu","sequence":"additional","affiliation":[{"name":"CVie Therapeutics Limited, Taipei, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6967-8758","authenticated-orcid":false,"given":"Gwo-Jyh","family":"Chang","sequence":"additional","affiliation":[{"name":"Graduate Institute of Clinical Medical Sciences, Chang Gung University, Tao-Yuan 33305, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabetta","family":"Boz","sequence":"additional","affiliation":[{"name":"Clinica Veterinaria Gran Sasso Via Donatello, 26, 20131 Milano, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4213-3173","authenticated-orcid":false,"given":"Emanuela","family":"Sala","sequence":"additional","affiliation":[{"name":"Department of Biotechnology and Biosciences, Universit\u00e0 degli Studi di Milano-Bicocca, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Vagni","sequence":"additional","affiliation":[{"name":"Department of Biotechnology and Biosciences, Universit\u00e0 degli Studi di Milano-Bicocca, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8743-9080","authenticated-orcid":false,"given":"Claudia","family":"Altomare","sequence":"additional","affiliation":[{"name":"Fondazione Cardiocentro Ticino, via Tesserete 48, Lugano 6900, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaspare","family":"Mostacciuolo","sequence":"additional","affiliation":[{"name":"Department of Biotechnology and Biosciences, Universit\u00e0 degli Studi di Milano-Bicocca, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3029-1155","authenticated-orcid":false,"given":"Claudio","family":"Bussadori","sequence":"additional","affiliation":[{"name":"Clinica Veterinaria Gran Sasso Via Donatello, 26, 20131 Milano, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrizia","family":"Ferrari","sequence":"additional","affiliation":[{"name":"Windtree Therapeutics Inc., Warrington, PA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Bianchi","sequence":"additional","affiliation":[{"name":"Windtree Therapeutics Inc., Warrington, PA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9191-4550","authenticated-orcid":false,"given":"Marcella","family":"Rocchetti","sequence":"additional","affiliation":[{"name":"Department of Biotechnology and Biosciences, Universit\u00e0 degli Studi di Milano-Bicocca, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,4,1]]},"reference":[{"key":"2022031721054114800_cvab123-B1","doi-asserted-by":"crossref","first-page":"4293","DOI":"10.1210\/jc.2012-3487","article-title":"Year in diabetes 2012: the diabetes tsunami","volume":"97","author":"Sherwin","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"2022031721054114800_cvab123-B2","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1159\/000064682","article-title":"Left ventricular diastolic dysfunction as an early manifestation of diabetic cardiomyopathy","volume":"98","author":"Schannwell","year":"2002","journal-title":"Cardiology"},{"key":"2022031721054114800_cvab123-B3","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1007\/s11906-004-0035-3","article-title":"Altered cardiac calcium handling in diabetes","volume":"6","author":"Belke","year":"2004","journal-title":"Curr Hypertens Rep"},{"key":"2022031721054114800_cvab123-B4","doi-asserted-by":"crossref","first-page":"3213","DOI":"10.1161\/CIRCULATIONAHA.106.679597","article-title":"Diabetic cardiomyopathy revisited","volume":"115","author":"Boudina","year":"2007","journal-title":"Circulation"},{"key":"2022031721054114800_cvab123-B5","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1038\/ncpcardio1347","article-title":"Interplay between impaired calcium regulation and insulin signaling abnormalities in diabetic cardiomyopathy","volume":"5","author":"Lebeche","year":"2008","journal-title":"Nat Clin Pract Cardiovasc Med"},{"key":"2022031721054114800_cvab123-B6","doi-asserted-by":"crossref","first-page":"H1398","DOI":"10.1152\/ajpheart.00313.2002","article-title":"Defective intracellular Ca2+ signaling contributes to cardiomyopathy in type 1 diabetic rats","volume":"283","author":"Choi","year":"2002","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"2022031721054114800_cvab123-B7","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1023\/B:MCBI.0000028762.97754.26","article-title":"Increased inhibition of SERCA2 by phospholamban in the type I diabetic heart","volume":"261","author":"Vasanji","year":"2004","journal-title":"Mol Cell Biochem"},{"key":"2022031721054114800_cvab123-B8","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1161\/CIRCRESAHA.111.259754","article-title":"Modulation of cardiac contractility by the phopholamban\/SERCA2a regulatome","volume":"110","author":"Kranias","year":"2012","journal-title":"Circ Res"},{"key":"2022031721054114800_cvab123-B9","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.2174\/1381612820666141029100650","article-title":"Calcium store stability as an antiarrhythmic endpoint","volume":"21","author":"Zaza","year":"2015","journal-title":"Curr Pharm Des"},{"key":"2022031721054114800_cvab123-B10","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1093\/cvr\/cvy226","article-title":"Telmisartan and thiorphan combination treatment attenuates fibrosis and apoptosis in preventing diabetic cardiomyopathy","volume":"115","author":"Malek","year":"2019","journal-title":"Cardiovasc Res"},{"key":"2022031721054114800_cvab123-B11","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1586\/erc.10.17","article-title":"Diabetic cardiomyopathy: signaling defects and therapeutic approaches","volume":"8","author":"Dobrin","year":"2010","journal-title":"Expert Rev Cardiovasc Ther"},{"key":"2022031721054114800_cvab123-B12","doi-asserted-by":"crossref","first-page":"501","DOI":"10.3389\/fphar.2018.00501","article-title":"Relaxin as a therapeutic target for the cardiovascular complications of diabetes","volume":"9","author":"Ng","year":"2018","journal-title":"Front Pharmacol"},{"key":"2022031721054114800_cvab123-B13","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.cardfail.2009.01.013","article-title":"Calcium upregulation by percutaneous administration of gene therapy in cardiac disease (CUPID Trial), a first-in-human phase 1\/2 clinical trial","volume":"15","author":"Jaski","year":"2009","journal-title":"J Card Fail"},{"key":"2022031721054114800_cvab123-B14","doi-asserted-by":"crossref","first-page":"44230","DOI":"10.1074\/jbc.M303810200","article-title":"Diabetes and the accompanying hyperglycemia impairs cardiomyocyte calcium cycling through increased nuclear O-GlcNAcylation","volume":"278","author":"Clark","year":"2003","journal-title":"J Biol Chem"},{"key":"2022031721054114800_cvab123-B15","doi-asserted-by":"crossref","first-page":"947","DOI":"10.2337\/db10-1145","article-title":"Carbonylation contributes to SERCA2a activity loss and diastolic dysfunction in a rat model of type 1 diabetes","volume":"60","author":"Shao","year":"2011","journal-title":"Diabetes"},{"key":"2022031721054114800_cvab123-B16","doi-asserted-by":"crossref","first-page":"7229","DOI":"10.1038\/ncomms8229","article-title":"Small-molecule activation of SERCA2a SUMOylation for the treatment of heart failure","volume":"6","author":"Kho","year":"2015","journal-title":"Nat Commun"},{"key":"2022031721054114800_cvab123-B17","doi-asserted-by":"crossref","first-page":"7806435","DOI":"10.1155\/2018\/7806435","article-title":"Addressing stem cell therapeutic approaches in pathobiology of diabetes and its complications","volume":"2018","author":"Peng","year":"2018","journal-title":"J Diabetes Res"},{"key":"2022031721054114800_cvab123-B18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejphar.2017.07.035","article-title":"A pyridone derivative activates SERCA2a by attenuating the inhibitory effect of phospholamban","volume":"814","author":"Kaneko","year":"2017","journal-title":"Eur J Pharmacol"},{"key":"2022031721054114800_cvab123-B19","doi-asserted-by":"crossref","first-page":"463","DOI":"10.2337\/diabetes.53.2.463","article-title":"Diabetes increases formation of advanced glycation end products on sarco(endo)plasmic reticulum Ca2+-ATPase","volume":"53","author":"Bidasee","year":"2004","journal-title":"Diabetes"},{"key":"2022031721054114800_cvab123-B20","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1016\/j.ahj.2009.03.007","article-title":"Effects of istaroxime on diastolic stiffness in acute heart failure syndromes: results from the Hemodynamic, Echocardiographic, and Neurohormonal Effects of Istaroxime, a Novel Intravenous Inotropic and Lusitropic Agent: a Randomized Controlled Trial in Patients Hospitalized with Heart Failure (HORIZON-HF) trial","volume":"157","author":"Shah","year":"2009","journal-title":"Am Heart J"},{"key":"2022031721054114800_cvab123-B21","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1124\/jpet.104.077933","article-title":"Modulation of sarcoplasmic reticulum function by Na+\/K + pump inhibitors with different toxicity: digoxin and PST2744 [(E,Z)-3-((2-aminoethoxy)imino)androstane-6,17-dione hydrochloride]","volume":"313","author":"Rocchetti","year":"2005","journal-title":"J Pharmacol Exp Ther"},{"key":"2022031721054114800_cvab123-B22","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1111\/bph.12278","article-title":"Istaroxime stimulates SERCA2a and accelerates calcium cycling in heart failure by relieving phospholamban inhibition","volume":"169","author":"Ferrandi","year":"2013","journal-title":"Br J Pharmacol"},{"key":"2022031721054114800_cvab123-B23","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1016\/j.yjmcc.2011.02.008","article-title":"Role and mechanism of subcellular Ca2+ distribution in the action of two inotropic agents with different toxicity","volume":"50","author":"Alemanni","year":"2011","journal-title":"J Mol Cell Cardiol"},{"key":"2022031721054114800_cvab123-B24","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1097\/00005344-200308000-00003","article-title":"Hemodynamic effects of a new inotropic compound, PST-2744, in dogs with chronic ischemic heart failure","volume":"42","author":"Adamson","year":"2003","journal-title":"J Cardiovasc Pharmacol"},{"key":"2022031721054114800_cvab123-B25","doi-asserted-by":"crossref","first-page":"24A","DOI":"10.1016\/j.amjcard.2006.09.003","article-title":"Istaroxime, a stimulator of sarcoplasmic reticulum calcium adenosine triphosphatase isoform 2a activity, as a novel therapeutic approach to heart failure","volume":"99","author":"Micheletti","year":"2007","journal-title":"Am J Cardiol"},{"key":"2022031721054114800_cvab123-B26","doi-asserted-by":"crossref","first-page":"41A","DOI":"10.1016\/j.amjcard.2006.09.005","article-title":"Hemodynamic properties of a new-generation positive luso-inotropic agent for the acute treatment of advanced heart failure","volume":"99","author":"Sabbah","year":"2007","journal-title":"Am J Cardiol"},{"key":"2022031721054114800_cvab123-B27","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1124\/jpet.108.138701","article-title":"Modulation of sarcoplasmic reticulum function by PST2744 [Istaroxime; (E,Z)-3-((2-aminoethoxy)imino) androstane-6,17-dione hydrochloride] in a pressure-overload heart failure model","volume":"326","author":"Rocchetti","year":"2008","journal-title":"J Pharmacol Exp Ther"},{"key":"2022031721054114800_cvab123-B28","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1002\/ejhf.1743","article-title":"Treatment with 24 hour istaroxime infusion in patients hospitalised for acute heart failure: a randomised, placebo-controlled trial","volume":"22","author":"Carubelli","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2022031721054114800_cvab123-B29","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1124\/jpet.102.038331","article-title":"Pharmacological profile of the novel inotropic agent (E,Z)-3-((2-aminoethoxy)imino)androstane-6,17-dione hydrochloride (PST2744)","volume":"303","author":"Micheletti","year":"2002","journal-title":"J Pharmacol Exp Ther"},{"key":"2022031721054114800_cvab123-B30","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1124\/jpet.102.047696","article-title":"Diverse toxicity associated with cardiac Na+\/K+ pump inhibition: evaluation of electrophysiological mechanisms","volume":"305","author":"Rocchetti","year":"2003","journal-title":"J Pharmacol Exp Ther"},{"key":"2022031721054114800_cvab123-B31","first-page":"141","article-title":"Combining SERCA2a activation and Na-K ATPase inhibition: a promising new approach to managing acute heart failure syndromes with low cardiac output","volume":"12","author":"Gheorghiade","year":"2011","journal-title":"Discov Med"},{"key":"2022031721054114800_cvab123-B32","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.phrs.2018.05.001","article-title":"Istaroxime, a positive inotropic agent devoid of proarrhythmic properties in sensitive chronic atrioventricular block dogs","volume":"133","author":"Bossu","year":"2018","journal-title":"Pharmacol Res"},{"key":"2022031721054114800_cvab123-B33","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1093\/cvr\/cvu188","article-title":"Ranolazine prevents INaL enhancement and blunts myocardial remodelling in a model of pulmonary hypertension","volume":"104","author":"Rocchetti","year":"2014","journal-title":"Cardiovasc Res"},{"key":"2022031721054114800_cvab123-B34","doi-asserted-by":"crossref","first-page":"C237","DOI":"10.1152\/ajpcell.00259.2014","article-title":"Automatic quantitative analysis of t-tubule organization in cardiac myocytes using ImageJ","volume":"308","author":"Pasqualin","year":"2015","journal-title":"Am J Physiol Cell Physiol"},{"key":"2022031721054114800_cvab123-B35","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1161\/01.HYP.28.6.1018","article-title":"Renal Na,K-ATPase in genetic hypertension","volume":"28","author":"Ferrandi","year":"1996","journal-title":"Hypertension"},{"key":"2022031721054114800_cvab123-B36","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1161\/CIRCEP.114.002572","article-title":"IKr impact on repolarization and its variability assessed by dynamic clamp","volume":"8","author":"Altomare","year":"2015","journal-title":"Circ Arrhythm Electrophysiol"},{"key":"2022031721054114800_cvab123-B37","doi-asserted-by":"crossref","first-page":"e003078","DOI":"10.1161\/JAHA.115.003078","article-title":"Reduction in Kv current enhances the temporal dispersion of the action potential in diabetic myocytes: insights from a novel repolarization algorithm","volume":"5","author":"Meo","year":"2016","journal-title":"J Am Heart Assoc"},{"key":"2022031721054114800_cvab123-B38","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/s11010-009-0074-9","article-title":"Altered gene expression may underlie prolonged duration of the QT interval and ventricular action potential in streptozotocin-induced diabetic rat heart","volume":"328","author":"Howarth","year":"2009","journal-title":"Mol Cell Biochem"},{"key":"2022031721054114800_cvab123-B39","first-page":"395","article-title":"Effects of streptozotocin diabetes and insulin treatment on myocardial sodium pump and contractility of the rat heart","volume":"222","author":"Ku","year":"1982","journal-title":"J Pharmacol Exp Ther"},{"key":"2022031721054114800_cvab123-B40","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1038\/nm739","article-title":"Chronic suppression of heart-failure progression by a pseudophosphorylated mutant of phospholamban via in vivo cardiac rAAV gene delivery","volume":"8","author":"Hoshijima","year":"2002","journal-title":"Nat Med"},{"key":"2022031721054114800_cvab123-B41","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1161\/CIRCULATIONAHA.108.783852","article-title":"Long-term cardiac-targeted RNA interference for the treatment of heart failure restores cardiac function and reduces pathological hypertrophy","volume":"119","author":"Suckau","year":"2009","journal-title":"Circulation"},{"key":"2022031721054114800_cvab123-B42","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/j.yjmcc.2004.06.009","article-title":"Phospholamban ablation by RNA interference increases Ca2+uptake into rat cardiac myocyte sarcoplasmic reticulum","volume":"37","author":"Watanabe","year":"2004","journal-title":"J Mol Cell Cardiol"},{"key":"2022031721054114800_cvab123-B43","doi-asserted-by":"crossref","first-page":"7018","DOI":"10.1016\/S0021-9258(19)62716-X","article-title":"Stimulation of bovine cardiac sarcoplasmic reticulum Ca2+ pump and blocking of phospholamban phosphorylation and dephosphorylation by a phospholamban monoclonal antibody","volume":"261","author":"Suzuki","year":"1986","journal-title":"J Biol Chem"},{"key":"2022031721054114800_cvab123-B44","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fphys.2019.00826","article-title":"Electrical conduction system remodeling in streptozotocin-induced diabetes mellitus rat heart","volume":"10","author":"Zhang","year":"2019","journal-title":"Front Physiol"},{"key":"2022031721054114800_cvab123-B45","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/S0024-3205(01)01141-9","article-title":"Diabetes related cardiomyopathy time dependent echocardiographic evaluation in an experimental rat model","volume":"69","author":"Mihm","year":"2001","journal-title":"Life Sci"},{"key":"2022031721054114800_cvab123-B46","doi-asserted-by":"crossref","first-page":"BSR20171307","DOI":"10.1042\/BSR20171307","article-title":"Apoptosis of cardiomyocytes in diabetic cardiomyopathy involves overexpression of glycogen synthase kinase-3\u03b2","volume":"39","author":"Wu","year":"2019","journal-title":"Biosci Rep"},{"key":"2022031721054114800_cvab123-B47","doi-asserted-by":"crossref","first-page":"166","DOI":"10.15420\/aer.2019.16.2","article-title":"The increment of short-term variability of repolarisation determines the severity of the imminent arrhythmic outcome","volume":"8","author":"Smoczynska","year":"2019","journal-title":"Arrhythm Electrophysiol Rev"}],"container-title":["Cardiovascular Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/cardiovascres\/advance-article-pdf\/doi\/10.1093\/cvr\/cvab123\/37022138\/cvab123.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cardiovascres\/article-pdf\/118\/4\/1020\/42950271\/cvab123.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cardiovascres\/article-pdf\/118\/4\/1020\/42950271\/cvab123.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,17]],"date-time":"2022-03-17T23:46:18Z","timestamp":1647560778000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cardiovascres\/article\/118\/4\/1020\/6207967"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,1]]},"references-count":47,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2021,4,1]]},"published-print":{"date-parts":[[2022,3,16]]}},"URL":"https:\/\/doi.org\/10.1093\/cvr\/cvab123","relation":{},"ISSN":["0008-6363","1755-3245"],"issn-type":[{"value":"0008-6363","type":"print"},{"value":"1755-3245","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,3,1]]},"published":{"date-parts":[[2021,4,1]]}}}